A growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.

John Shannon was appointed Chief Executive Officer in August 2024.  He joined Xeris in 2017 as Chief Operating Officer and was promoted to President in 2020.  Mr. Shannon has 35+ years of pharmaceutical and healthcare experience with a diverse background in sales, global and US marketing, operations and manufacturing, strategic planning, and business development.

Prior to Xeris, Mr. Shannon spent two years as Chief Executive Officer for Catheter Connections, Inc., a company focused on the development and commercialization of innovative vascular access products designed to protect patients from acquiring infections during intravenous infusion therapy. Catheter Connections, Inc. was acquired by Merit Medical in January 2016.

Before Catheter Connections, Mr. Shannon spent three years as Chief Commercial Officer for Durata Therapeutics, a biopharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions to advance patient care in infectious disease and acute illnesses. Durata was acquired by Actavis (now Allergan) in November 2014. Mr. Shannon spent 10 years (2001–2011) at Baxter Healthcare, where he was General Manager, Global Hemophilia and Global Commercial Excellence; General Manager, US Biopharmaceuticals; Vice President, Marketing US Bioscience; and Vice President, Marketing US Renal. During his time at Baxter, he led the commercialization and drove the growth of two Baxter brands, ADVATE® and GAMMAGARD®, both of which now exceed revenues of $1 billion.

Prior to coming to Baxter, Mr. Shannon was Vice President, Marketing for Caremark. Before that, he was at Searle for 10 years; there, he held several positions, most notably Executive Director, Cardiovascular Global Commercialization, in which he was responsible for the commercial development and marketing of new cardiovascular products worldwide, and Senior Director of Cox-2 Global Commercialization, in which he led the worldwide launch and global marketing of Celebrex®. In addition, he spent 7 years at Bock Pharmacal Company, where he held various positions including Sales Representative, Sales Trainer, Sales Operations, Marketing, Strategic Planning, and Business Development.

Mr. Shannon holds a BS in Biology with an emphasis in Microbiology from Western Illinois University.

Kevin McCulloch was named President and Chief Operating Officer of Xeris in August 2024.  He joined Xeris Pharmaceuticals in October 2018 as Senior Vice President, Global Operations and Business Development and was named Chief Commercial Officer in September 2021. Mr. McCulloch has spent more than 35 years in the pharmaceutical and medical device industry in diverse leadership and general management roles spanning sales, marketing, and business operations for both US and international entities.

Prior to joining Xeris, Kevin was the President of Global Solutions at Hill-Rom and earlier, as Chief Business Officer for Water Street Healthcare Partners Pharmaceutical Holdings. Mr. McCulloch spent 15 years with Baxter Healthcare in successive management roles including GM/President of the Global Services, Global Fluid Systems (GFS), Infusion Systems (IS), and Fenwal business units. While the leader of GFS, he created Celerity Pharmaceuticals, one of the industry’s first R&D externalization ventures that has since successfully generated multiple new product launches. As leader of the IS business, he oversaw the acquisition and integration of Sigma International into the IS portfolio while successfully navigating the business out of a long-standing consent decree. As the President of Fenwal, a global leader in blood collection and apheresis technology, Mr. McCulloch led its successful divestiture to TPG in 2007. He started his Baxter career as a Vice President of Global Marketing in the Renal division. Prior to Baxter, Mr. McCulloch spent 9 years at GD Searle in roles of increasing responsibility in business development, marketing, and sales. He began his career as a territory sales representative with the Upjohn Company.

Mr. McCulloch holds an MBA from Northwestern University’s Kellogg School of Management and a BS in Biology from the University of Michigan.
 

Kendal Korte is the Senior Vice President of Human Resources for Xeris Pharmaceuticals and has led the function since its inception in 2017. In addition to Human Resources, during her tenure she has led multiple functions for the Company, including IT and Corporate Administration. 

Ms. Korte brings 20 years of multi-faceted human resources experience across multiple industries including professional services, real estate, steel manufacturing and most recently, biotechnology and pharmaceuticals. Ms. Korte has previously served as the head of human resources at Catheter Connections, Inc, which was acquired by Merit Medical Systems, Inc in 2016. Prior to this engagement, Ms. Korte served in various human resources roles at Durata Therapeutics, EVRAZ North America, Equity Residential, and SmithBucklin Corporation.

Ms. Korte received her master’s degree in human resources management from North Park University in Chicago, IL and holds various certifications in the field of human resources.

Brian Conner serves as Senior Vice President of Quality and Chief Compliance and Risk Officer of Xeris Pharmaceuticals. He brings 30+ years of biopharmaceutical industry experience within the areas of corporate ethics and compliance, quality, regulatory affairs, general management, basic R&D, manufacturing, sales/marketing and medical advertising.  

Prior to joining Xeris, Mr. Conner served as Chief Compliance Officer at Strongbridge Biopharma prior to being acquired by Xeris in the Fall of 2021. Prior to these positions, Mr. Conner served as the Assistant Compliance Officer for the U.S and Canada at Shire Pharmaceuticals. During his career, Mr. Conner has established and led compliance, quality, regulatory teams and /research facilities, and held an array senior level positions at Stiefel Laboratories, Genzyme, Biogen, Saatchi and Saatchi and Merck. Mr. Conner is a graduate of Drexel University.
 

Dr. Anh Nguyen serves as Chief Medical Officer, leading clinical development, regulatory strategy, and medical affairs to advance innovative therapies for patients with rare diseases and complex conditions. With a strong focus on translational medicine and patient-centered drug development, Dr. Nguyen drives cross-functional collaboration to bring next-generation therapies from discovery to commercialization.  

Dr. Nguyen has more than 20 years of experience spanning biopharmaceutical leadership across small molecules, biologics, RNA therapeutics, and cell and gene therapies. His experience spans early through late-stage drug development and commercial launch - including drug discovery, translation medicine, CMC, regulatory affairs, clinical development, medical affairs, pharmacovigilance, and market access. He led multiple IND submissions for first-in-class therapies, including circular RNA treatments for oncology, immuno-oncology vaccines, gene-edited solid organ xenotransplants, and allogeneic CAR-T therapies. Prior he was Vice President, Therapeutic Sector Lead at Asklepios Biopharmaceutical (AskBio), where he guided the IND clearance and early-phase clinical trials for AAV gene therapies targeting heart failure and neuromuscular rare disease.  

Dr. Nguyen also held key leadership roles at Xeris Pharmaceuticals, where he served as Program Medical Lead for Gvoke®’s NDA and MAA approvals and multiple IND clearances in endocrine and rare disease indications. Earlier in his career, he served as Global Medical Director at Baxter Healthcare, where he oversaw clinical trials and regulatory submissions for drugs, devices, and biologics across immunology, nephrology, pulmonology, cardiovascular, and digital health.  

Dr. Nguyen has deep expertise in federal regulatory and policy development, having served as a Medical Officer and clinical reviewer at the U.S. Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS). At the FDA, he contributed to regulatory strategy, combination product approvals, and policy guidance for digital health and combination products. While at CMS, he conducted coverage analyses for novel therapeutics and helped shape Medicare policy. As a Robert Wood Johnson Foundation Health Policy Fellow and Senate Committee Staffer, Dr. Nguyen played a pivotal role in drafting components of the landmark "21st Century Cures Act", which strengthened U.S. biomedical innovation and became law in 2016.  

Dr. Nguyen’s commitment to advancing medical science was further recognized during his tenure at the National Institutes of Health (NIH), where he led the establishment of an ambulatory surgical service to expedite pediatric orphan disease and oncology trials. His contributions in developing and executing early-stage pediatric trials in oncology, neurology, and rare metabolic disorders earned him the prestigious NIH Director’s Award.  

Dr. Nguyen holds an MD from Rutgers New Jersey Medical School and an MBA with a concentration in finance from the University of Chicago Booth School of Business. He completed his residency and fellowship training in anesthesiology and cardiovascular anesthesia at Massachusetts General Hospital, Harvard Medical School.